Targeted Drug Combinations for Advanced Non-Small Cell Lung Cancer with EGFR and MET Gene Changes

Short Title: S1900G

Enrollment Status: Recruiting

NCT #: NCT05642572

Specialty Area: Oncology

Condition Studied: Advanced or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Age Groups: Adult; Older Adult

Phase: II

Study Information

Summary / Purpose

To find out if combining targeted medications that block EGFR and MET gene changes can help shrink or control advanced lung cancer.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with Non-Small Cell Lung Cancer (NSCLC) that has spread (advanced) or recurrent
Cancer must be EGFR-mutated with extra copies of the MET gene (MET amplification)
Must be eligible to receive targeted therapy

What's Involved

Participation in the study will include:

Treatment with capmatinib and osimertinib given orally with or without ramucirumab given intravenously (IV)
CT scans and MRI to monitor response to treatment
Blood and tissue sample collection to monitor your health and treatment effects
Questionnaires

Principal Investigator

Katharine Thomas, MD

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT05642572

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews